إعلان
إعلان

ENLV

ENLV logo

Enlivex Therapeutics Ltd. Ordinary Shares

0.84
USD
برعاية
+0.02
+2.18%
٠٨ يناير, ١٥:٥٩ UTC -5
مغلق
exchange

بعد الإغلاق

0.84

0.00
-0.48%

تقارير أرباح ENLV

النسبة الإيجابية المفاجئة

ENLV تفوق 17 من 29 آخر التقديرات.

59%

التقرير التالي

بيانات التقرير القادم
٣٠ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.11
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/
+22.22%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/
-52.17%

Enlivex Therapeutics Ltd. Ordinary Shares earnings per share and revenue

On ١٤ نوفمبر ٢٠٢٥, ENLV reported earnings of -0.09 USD per share (EPS) for Q3 25, beating the estimate of -0.12 USD, resulting in a 26.47% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.63% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 المحللين forecast an EPS of -0.11 USD, with revenue projected to reach -- USD, implying an زيادة of 22.22% EPS, and زيادة of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
٢٦ ديسمبر ٢٠٢٥ إلى ربع سنوي4 25
تقدير
-$0.49
الفعلي
-
مفاجئة
-
الأسئلة الشائعة
For Q3 2025, Enlivex Therapeutics Ltd. Ordinary Shares reported EPS of -$0.09, beating estimates by 26.47%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.63%, changed from $0.99 before the earnings release to $0.98 the day after.
The next earning report is scheduled for ٣٠ مارس ٢٠٢٦.
Based on 3 المحللين, Enlivex Therapeutics Ltd. Ordinary Shares is expected to report EPS of -$0.11 and revenue of -- for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان